BPC-157 increases the expression of growth hormone receptors on fibroblasts, boosting the longevity of these cells and thus their ability to promote soft tissue regeneration [3]
Semaglutide (Wegovy, Ozempic) received FDA approval for chronic weight management in 2021, followed by tirzepatide (Zepbound) in 2023, both demonstrating substantial weight loss in clinical trials
The medications made available through Omzo's program are prescription pharmaceutical preparations, not dietary supplements or over-the-counter consumer products subject to Proposition 65 botanical heavy-metals concerns
Understanding oral versus injectable peptide delivery helps contextualize why this matters
Weight regain is common if you stop without maintaining the habits (calorie control, protein intake, training) that support weight maintenance
What Documentation Should Be Reviewed First